DEFINITIVE CONTRACT
Active75A50126C00007
Department of Health and Human Services › Office of Assistant Secretary for Preparedness and Response › BARDA - ASPR / DAAPPO / BARDA DCMA
$18.5M
obligated · signed 1 week ago
ADVANCE THE DEVELOPMENT OF SCY-247, A NOVEL ANTIFUNGAL CURRENTLY IN PHASE 1 CLINICAL TRIALS, FOR THE TREATMENT OF INVASIVE CANDIDIASIS AND PROPHYLAXIS OF INVASIVE FUNGAL DISEASE AS ORAL AND IC FORMULA
Performance timeline
Start
Sep 15, 2026
End
Jul 31, 2032
with all options
Loading status
Estimated start: Jul 31, 2031
SCYNEXIS INC
Contract 75A50126C00007
UEI
H6PSJYEW3DT9
Parent Company
SCYNEXIS INC
Capabilities & Certifications
Headquarters Location
Congressional District: 08
Current Obligation
$18,454,788
Base + Exercised Options
$18,454,788
Total Ceiling Value
$213,943,726
Contract Type
COST NO FEE
Multi-Year Contract
NO
NAICS
RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
PSC
HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT
Place of Performance
Congressional District: 08
Awarding Agency
Top-tier agency
Office of Assistant Secretary for Preparedness and Response
Sub-tier agency
BARDA - ASPR / DAAPPO / BARDA DCMA
Office
Funding Agency
Top-tier agency
Office of Assistant Secretary for Preparedness and Response
Sub-tier agency
BARDA - ASPR / DAAPPO / BARDA DCMA
Office
Solicitation procedures, competition exceptions, labor standards and account totals.